Indicated in the treatment of acute & chronic peripheral and cerebral vascular metabolic disorders, Raynaud's syndrome and all syndromes due to altered peripheral flow.
Nicergoline has a broad spectrum of action: (i) as an alpha adrenoceptor antagonist, it induces vasodilation and increases arterial blood flow; (ii) it enhances cholinergic and catecholaminergic neurotransmitter function; (iii) it inhibits platelet aggregation; (iv) it promotes metabolic activity, resulting in increased utilization of oxygen and glucose; and (v) it has neurotrophic and antioxidant properties
30 mg/day in Cerebrovascular insufficiency. 30 mg twice per day, for Peripheral Vasodilatation.
Contraindicated in hypersensitivity to nicergoline or any of the drug constituents
Nicergoline, as other adrenergic blocking agents, may significantly reduce blood pressure (arterial hypotension) in some patients.
Do not administer this product if pregnant, if pregnancy is suspected or during breast-feeding. There are no adequate and well-controlled studies in this population hence should not be used.
Nicergoline is known to potentiate the cardiodepressant effects of propranolol.
Drowsiness, tiredness, constipation, pyrosis, vomiting, diarrhea, facial flushing, sexual impotence and libido reduction, uric acid increment